| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Julie Johnson TX32 | 1 | 3 | −$16.0K | Bought Sep 23, 25 |
| Lisa McClain MI09 | 1 | 1 | +$0 | Sold Jul 16, 25 |
| Rob Bresnahan PA08 | 1 | 1 | +$0 | Bought May 15, 25 |
| Jefferson Shreve IN06 | 1 | 2 | −$32.5K | Sold May 12, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Sep 23, 25 | Julie Johnson TX32 | Joint | Buy | $1,001 - $15,000 | Aug 5, 26 (316d) | |
| Sep 23, 25 | Julie Johnson TX32 | Joint | Sell | $1,001 - $15,000 | Aug 5, 26 (316d) | |
| Jul 16, 25 | Lisa McClain MI09 | Spouse | Sell | $1,001 - $15,000 | Aug 13, 25 (28d) | |
| Jun 17, 25 | Lisa McClain MI09 | Spouse | Buy | $1,001 - $15,000 | Aug 13, 25 (57d) | |
| May 15, 25 | Rob Bresnahan PA08 | Self | Buy | $1,001 - $15,000 | May 31, 25 (16d) | |
| May 12, 25 | Jefferson Shreve IN06 | Self | Sell | $15,001 - $50,000 | Jun 22, 25 (41d) | |
| Apr 17, 25 | Jefferson Shreve IN06 | Self | Buy | $15,001 - $50,000 | May 8, 25 (21d) | |
| Apr 8, 25 | Rob Bresnahan PA08 | Self | Sell | $1,001 - $15,000 | Apr 28, 25 (20d) | |
| Apr 1, 25 | Julie Johnson TX32 | Joint | Sell (part) | $1,001 - $15,000 | May 14, 25 (43d) | |
| Mar 13, 25 | Jefferson Shreve IN06 | Self | Sell | $15,001 - $50,000 | Apr 11, 25 (29d) | |
| Mar 3, 25 | Julie Johnson TX32 | Joint | Sell | $1,001 - $15,000 | Apr 14, 25 (42d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 7, 2026 | Boehnlein Glenn SDirector | Stock Award(Grant) at price 146.85 per share. | 817 | $119.98K |
| Sep 3, 2026 | Dolsten MikaelDirector | Sale at price 151.38 per share. | 634 | $95.97K |
| May 28, 2026 | Dolsten MikaelDirector | Sale at price 135.42 per share. | 1.6K | $216.67K |
| May 18, 2026 | Buckner Michael StevenOfficer | Stock Award(Grant) at price 0.00 per share. | 8.9K | — |
| Mar 18, 2026 | Brawley Otis WDirector | Stock Award(Grant) at price 111.75 per share. | 3K | $340.39K |
| Mar 18, 2026 | Wilson Dow RDirector | Stock Award(Grant) at price 111.75 per share. | 2.2K | $241.16K |
| Mar 18, 2026 | Brown Judy Lynne GawlikDirector | Stock Award(Grant) at price 111.75 per share. | 2.2K | $241.16K |
| Mar 18, 2026 | Scangos George ADirector | Stock Award(Grant) at price 111.75 per share. | 3.2K | $359.28K |
| Mar 18, 2026 | Koh Boon HweeDirector | Stock Award(Grant) at price 111.75 per share. | 2.2K | $241.16K |
| Mar 18, 2026 | Anand MalaDirector | Stock Award(Grant) at price 111.75 per share. | 2.2K | $241.16K |
| Mar 18, 2026 | Rataj Sue HDirector | Stock Award(Grant) at price 111.75 per share. | 2.2K | $241.16K |
| Mar 18, 2026 | Dolsten MikaelDirector | Stock Award(Grant) at price 111.75 per share. | 2.2K | $241.16K |
| Mar 18, 2026 | Podolsky Daniel KDirector | Stock Award(Grant) at price 111.75 per share. | 2.2K | $241.16K |
| Mar 18, 2026 | Soriot PascalDirector | Stock Award(Grant) at price 111.75 per share. | 2.2K | $241.16K |
| Nov 30, 2025 | Dolsten MikaelDirector | Sale at price 149.81 per share. | 2.6K | $389.51K |
| Nov 25, 2025 | Gonsalves RodneyOfficer | Stock Gift at price 154.37 per share. | 400 | $61.75K |
| Nov 25, 2025 | Gonsalves RodneyOfficer | Sale at price 154.99 per share. | 3K | $464.96K |
| Nov 17, 2025 | Dimarco Bret MOfficer | Stock Award(Grant) at price 0.00 per share. | 6.9K | — |
| Nov 17, 2025 | Riemann AngelicaOfficer | Stock Award(Grant) at price 0.00 per share. | 8.3K | — |
| Nov 17, 2025 | Kirkwood Jonah PrevostOfficer | Stock Award(Grant) at price 0.00 per share. | 7.5K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.6 | -9.3 | -6.1 | 1.4 | 17.3 | -2.0 | 4.2 | 11.0 | 12.2 | -0.6 | +25.9% | ||
| 2025 | 12.8 | -15.6 | -8.6 | -8.0 | 4.0 | 5.4 | -2.7 | 9.5 | 2.1 | 14.0 | 4.9 | -11.4 | +1.3% |
| 2024 | -6.4 | 5.6 | 5.9 | -5.8 | -4.8 | -0.6 | 9.1 | 1.1 | 3.9 | -12.2 | 5.9 | -2.6 | −3.4% |
| 2023 | 1.6 | -6.6 | -2.6 | -2.1 | -14.6 | 4.0 | 1.3 | -0.6 | -7.6 | -7.6 | 23.6 | 8.8 | −7.1% |
| 2022 | -12.7 | -6.4 | 1.5 | -9.9 | 7.0 | -6.9 | 12.9 | -4.4 | -5.2 | 13.8 | 12.0 | -3.4 | −6.3% |
| 2021 | 1.4 | 1.6 | 4.2 | 5.1 | 3.4 | 7.0 | 3.7 | 14.5 | -10.2 | -0.0 | -4.2 | 5.8 | +34.7% |
| 2020 | -3.2 | -6.6 | -7.1 | 7.0 | 15.0 | 0.3 | 9.0 | 4.2 | 0.5 | 1.1 | 14.5 | 1.4 | +38.9% |
| 2019 | 12.7 | 4.5 | 1.2 | -2.3 | -14.6 | 11.4 | -7.0 | 2.4 | 7.8 | -1.1 | 6.6 | 5.6 | +26.5% |
| 2018 | 9.6 | -6.6 | -2.5 | -1.7 | -5.8 | -0.1 | 6.8 | 2.3 | 4.4 | -8.2 | 11.7 | -6.8 | +0.7% |
| 2017 | 7.5 | 4.8 | 3.1 | 4.1 | 9.6 | -1.7 | 0.8 | 8.2 | -0.8 | 6.0 | 1.8 | -3.3 | +47.0% |
| 2016 | -9.9 | -0.8 | 6.7 | 2.7 | 12.1 | -3.3 | 8.5 | -2.3 | 0.2 | -7.5 | 0.9 | 3.6 | +9.0% |
| 2015 | -7.7 | 11.8 | -1.6 | -0.4 | -0.4 | -6.3 | 6.1 | -11.3 | -5.5 | 10.0 | 10.8 | -0.0 | +2.1% |
| 2014 | 1.7 | -2.1 | -1.8 | -3.4 | 5.4 | 0.9 | -2.4 | 1.9 | -0.3 | -3.0 | 8.1 | -4.2 | +0.1% |
| 2013 | 9.4 | -7.4 | 1.2 | -1.3 | 9.7 | -5.9 | 4.6 | 4.3 | 9.9 | -1.0 | 5.5 | 6.8 | +39.7% |
| 2012 | 21.6 | 2.7 | 2.0 | -5.2 | -3.6 | -3.5 | -2.4 | -3.0 | 3.5 | -6.4 | 6.4 | 6.9 | +17.2% |
| 2011 | 1.0 | 0.6 | 6.4 | 11.5 | -0.1 | 2.5 | -17.5 | -12.5 | -15.2 | 18.6 | 1.2 | -6.9 | −15.7% |
| 2010 | -9.8 | 12.2 | 9.3 | 5.4 | -10.8 | -12.1 | -1.8 | -3.4 | 23.7 | 4.3 | 0.6 | 18.3 | +33.3% |
| 2009 | 15.7 | -23.3 | 10.8 | 18.8 | -0.2 | 11.4 | 14.3 | 10.6 | 8.4 | -11.1 | 16.9 | 7.4 | +98.8% |
| 2008 | -7.8 | -9.6 | -2.5 | 1.3 | 23.8 | -4.9 | 1.5 | -3.6 | -14.7 | -25.2 | -15.1 | -17.0 | −57.5% |
| 2007 | -8.2 | -0.8 | 6.1 | 2.0 | 11.1 | 0.7 | -0.8 | -4.6 | 1.3 | -0.1 | 2.7 | -2.9 | +5.4% |
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Buy / hold / sell counts